- Home
- TAC vs APGE Comparison
TAC vs APGE Comparison
Compare TAC & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAC
- APGE
- Stock Information
- Founded
- TAC 1909
- APGE 2022
- Country
- TAC Canada
- APGE United States
- Employees
- TAC N/A
- APGE N/A
- Industry
- TAC Electric Utilities: Central
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TAC Utilities
- APGE Health Care
- Exchange
- TAC Nasdaq
- APGE Nasdaq
- Market Cap
- TAC 3.1B
- APGE 3.0B
- IPO Year
- TAC N/A
- APGE 2023
- Fundamental
- Price
- TAC $14.45
- APGE $39.46
- Analyst Decision
- TAC
- APGE Strong Buy
- Analyst Count
- TAC 0
- APGE 5
- Target Price
- TAC N/A
- APGE $83.50
- AVG Volume (30 Days)
- TAC 1.4M
- APGE 470.7K
- Earning Date
- TAC 02-20-2025
- APGE 03-04-2025
- Dividend Yield
- TAC 1.18%
- APGE N/A
- EPS Growth
- TAC N/A
- APGE N/A
- EPS
- TAC 0.38
- APGE N/A
- Revenue
- TAC $2,065,953,587.00
- APGE N/A
- Revenue This Year
- TAC N/A
- APGE N/A
- Revenue Next Year
- TAC N/A
- APGE N/A
- P/E Ratio
- TAC $37.61
- APGE N/A
- Revenue Growth
- TAC N/A
- APGE N/A
- 52 Week Low
- TAC $5.94
- APGE $32.78
- 52 Week High
- TAC $14.64
- APGE $72.29
- Technical
- Relative Strength Index (RSI)
- TAC 66.89
- APGE 39.14
- Support Level
- TAC $12.78
- APGE $36.48
- Resistance Level
- TAC $14.60
- APGE $42.98
- Average True Range (ATR)
- TAC 0.49
- APGE 2.94
- MACD
- TAC -0.05
- APGE -0.81
- Stochastic Oscillator
- TAC 91.48
- APGE 21.16
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, hydro, wind & solar, Energy Marketing, gas, energy transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.